Drug Repositioning is an Alternative for the Treatment of Coronavirus COVID-19

Overview

Journal Int J Antimicrob Agents

Specialties Infectious Diseases
Pharmacology

Date 2020 Apr 13

PMID 32278811

Citations 58

Authors

Marissa B Serafin

Angelita Bottega

Vitoria S Foletto

Tacieli F da Rosa

Andreas Horner

Rosmari Horner

Affiliations

Soon will be listed here.

Abstract

Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease.

Citing Articles

Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.

Petcherski A, Tingley B, Martin A, Adams S, Brownstein A, Steinberg R Life Sci Alliance. 2025; 8(4).

PMID: 39900438 PMC: 11790838. DOI: 10.26508/lsa.202403182.

How does a extract influence the components of isolated rotavirus particles from stool samples collected in a clinical setting from children?.

Hussein M, Al-Zaban M, Mahmoud Y, Al-Doaiss A, Bahshwan S, El-Dougdoug K Saudi J Biol Sci. 2024; 31(8):104031.

PMID: 38946847 PMC: 11214517. DOI: 10.1016/j.sjbs.2024.104031.

Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.

Xu J, Abdulsalam Khaleel R, Zaidan H, Mutee A, Fahmi Fawy K, Gehlot A Cell Cycle. 2024; 23(4):405-434.

PMID: 38640424 PMC: 11529202. DOI: 10.1080/15384101.2024.2340859.

Drug Repurposing: A Leading Strategy for New Threats and Targets.

Mishra A, Vasanthan M, Malliappan S ACS Pharmacol Transl Sci. 2024; 7(4):915-932.

PMID: 38633585 PMC: 11019736. DOI: 10.1021/acsptsci.3c00361.

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study.

Kim G, Moon H, Kim T, Yun S, Yun H, Hong J Pharmaceutics. 2023; 15(9).

PMID: 37765325 PMC: 10534584. DOI: 10.3390/pharmaceutics15092357.

References

Dyall J, Coleman C, Hart B, Venkataraman T, Holbrook M, Kindrachuk J . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8):4885-93. PMC: 4136000. DOI: 10.1128/AAC.03036-14. View

Zheng W, Sun W, Simeonov A . Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol. 2017; 175(2):181-191. PMC: 5758396. DOI: 10.1111/bph.13895. View

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H . Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020; 6:16. PMC: 7078228. DOI: 10.1038/s41421-020-0156-0. View

Wang L, Wang Y, Ye D, Liu Q . Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948]. Int J Antimicrob Agents. 2020; 56(3):106137. PMC: 7434381. DOI: 10.1016/j.ijantimicag.2020.106137. View

Sun M, Yang J, Sun Y, Su G . [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(0):E014. DOI: 10.3760/cma.j.issn.1001-0939.2020.0014. View

Lin M, Moses D, Hsieh C, Cheng S, Chen Y, Sun C . Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res. 2018; 150:155-163. PMC: 7113793. DOI: 10.1016/j.antiviral.2017.12.015. View

10.

Gordon D, Jang G, Bouhaddou M, Xu J, Obernier K, White K . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020; 583(7816):459-468. PMC: 7431030. DOI: 10.1038/s41586-020-2286-9. View

11.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

12.

Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M . Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009; 53(8):3416-21. PMC: 2715625. DOI: 10.1128/AAC.01509-08. View

13.

de Wilde A, Zevenhoven-Dobbe J, van der Meer Y, Thiel V, Narayanan K, Makino S . Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011; 92(Pt 11):2542-2548. PMC: 3352363. DOI: 10.1099/vir.0.034983-0. View

14.

Bolson Serafin M, Horner R . Drug repositioning, a new alternative in infectious diseases. Braz J Infect Dis. 2018; 22(3):252-256. PMC: 9425657. DOI: 10.1016/j.bjid.2018.05.007. View

15.

Baron S, Devaux C, Colson P, Raoult D, Rolain J . Teicoplanin: an alternative drug for the treatment of COVID-19?. Int J Antimicrob Agents. 2020; 55(4):105944. PMC: 7102624. DOI: 10.1016/j.ijantimicag.2020.105944. View

16.

de Wilde A, Jochmans D, Posthuma C, Zevenhoven-Dobbe J, van Nieuwkoop S, Bestebroer T . Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014; 58(8):4875-84. PMC: 4136071. DOI: 10.1128/AAC.03011-14. View

17.

Pfefferle S, Schopf J, Kogl M, Friedel C, Muller M, Carbajo-Lozoya J . The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011; 7(10):e1002331. PMC: 3203193. DOI: 10.1371/journal.ppat.1002331. View

18.

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323(1):264-8. PMC: 7092815. DOI: 10.1016/j.bbrc.2004.08.085. View